Citron Research: Not Dialing Back Warning on Valeant Pharma (VRX), Dialing Back on Citron Focus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Valeant Pharma (VRX) Issues Dear Doctor Letter; Philidor Issues Release - Evercore ISI
November 2, 2015 9:04 PM ESTEvercore ISI analyst Umer Raffat noted two new developments in the Valeant Pharma (NYSE: VRX) saga. First the company sent a dear doctor letter to dermatologists and separately, Philidor issued a press release.
Raffat highlighted the following from the letter:
For... MoreDead Cat Bounce, Or is a Sustainable Relief Rally in Store for Valeant (VRX)?
November 2, 2015 3:17 PM ESTCitron Research founder Andrew Left's decision to step back from publishing incremental negative research on Valeant (NYSE: VRX) does absolutely nothing to change the fact that there are things we simply don't know about the company's financials, however it does temporarily remove the threat of death by 1000 tweets. This could open the door for analysts who had been supportive of the company... More
Valeant Pharma (VRX) on Watch Ahead of Citron Left Interview
November 2, 2015 11:05 AM ESTBouncing 8% in early trade after Citron Research dialed back on the explosiveness of its report, Valeant Pharma (NYSE: VRX) is on watch ahead of Citron's Andrew Left interview on CNBC at 12PM ET.
Left... More
Citron Research: Don't Expect Anything Earth-Shattering on Valeant (VRX) Come Monday
November 1, 2015 7:32 PM ESTCitron Research's Andrew Left is dialing back on what investors should expect when he updates his report on battered Valeant Pharma (NYSE: VRX) on Monday.
During Bill Ackman's 4-hour defense of Valeant on Friday, short seller Left tweeted: "$VRX has a... More
